On Monday, in the course of current trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), dropped 0.79%, and is now trading at $66.30.
Chase declared the latest enhancement to its award-winning mobile app with the addition of Touch ID authentication for iPhones (5s, 6 and 6 plus), becoming one of the first U.S. banks to offer the feature.
Touch ID uses a customer’s fingerprint as another quick, convenient and secure way for customers to log in to the Chase Mobile app for iPhone. To complete secure transactions, such as Chase QuickPay℠, customers will enter their passwords for additional authentication.
This spring, JPMorgan Chase’s active mobile customer base surpassed 20 million – up 22 percent year over year. In 2014, Chase released the redesigned Chase Mobile® app for iPhone and Android™, receiving high praise in reviews from customers.
Other highlights comprise:
- Chase QuickPay via mobile devices was up 80% in 2014
- Chase QuickDeposit℠ - depositing checks by taking a picture with a mobile device – was done 45 million times last year
- Chase is now part of the clearXchange network, which makes it easier for Chase customers to send and receive money to more than 100 million customers from other banks.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
During an Early trade, Shares of Splunk, Inc. (NASDAQ:SPLK), dipped -1.73%, and is now trading at $66.45.
Splunk, declared that Dave Conte, chief financial officer, Splunk, will take part in a fireside chat at the Bank of America Merrill Lynch 2015 Global Technology Conference on Tuesday, June 2, 2015 in San Francisco.
Mr. Conte’s remarks will be webcast live starting at 10 a.m. PDT.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company’s products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users.
Shares of KeyCorp. (NYSE:KEY), during its Monday’s current trading session fell -0.17%, and is now trading at $14.56.
KeyCorp., declared at its annual meeting that shareholders can expect the company to remain “Focused Forward” in 2015 and continue to deliver on its planned priorities, drive profitable growth, and effectively manage both risk and capital.
“We delivered on our commitments in 2014,” said Beth Mooney, CEO and Chairman, KeyCorp. “Key attained and expanded client relationships, drove growth in loans and fee income, and improved productivity and efficiency, all while remaining disciplined with risk and capital. I am proud of our results and accomplishments on behalf of our shareholders, clients, and employees.”
During the annual meeting, shareholders elected 14 nominees to Key’s Board of Directors, each with noteworthy experience in a variety of national and international organizations across a number of industries. Additionally, Bruce Broussard, CEO and Chairman of Humana, Inc., a leading health and well-being company, was elected to the Board for the first time. “Bruce is a seasoned, thoughtful leader and a financially astute executive who believes strongly in giving back to the community,” said Mooney.
KeyCorp operates as the bank holding company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the United States.
Finally, Zogenix, Inc. (NASDAQ:ZGNX), lost -0.59% Monday.
Zogenix, declared new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria (see study data here). Zogenix intends to initiate Phase 3 clinical studies for ZX008, the Company’s investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome.
Patients with Dravet syndrome experience frequent, severe and potentially life-threatening seizures that typically start in the first year of life. These seizures do not respond to standard anti-epileptic medications and current treatment options are very limited.
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product comprises Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.